Susan D. Wyrick - 02 Mar 2025 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
Acting Chief Financial Officer and Principal Accounting Officer
Signature
/s/ Susan D. Wyrick
Issuer symbol
SANA
Transactions as of
02 Mar 2025
Net transactions value
-$1,254
Form type
4
Filing time
03 Mar 2025, 19:28:58 UTC
Previous filing
03 Jan 2025
Next filing
10 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SANA Common Stock Options Exercise $0 +1,525 +0.99% $0.000000 155,471 02 Mar 2025 Direct
transaction SANA Common Stock Tax liability $1,254 -490 -0.32% $2.56 154,981 03 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SANA Restricted Stock Units Options Exercise $0 -1,525 -33% $0.000000 3,050 02 Mar 2025 Common Stock 1,525 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
F2 The award vested as to 25% of the restricted stock units on each of March 2, 2024 and 2025, and the remaining restricted stock units vest in two equal installments on each of March 2, 2026 and 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Remarks:

Acting Chief Financial Officer and Principal Accounting Officer